Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: J Immunol. 2015 Feb 20;194(7):3487–3500. doi: 10.4049/jimmunol.1401717

Fig. 6. TCR chain centricity is observed with other HLA-restricted antitumor TCRs.

Fig. 6

(A), Peripheral CD8+ T cells transduced with 1G4α, 1G4β, or 1G4LYα recognize A2/NY-ESO-1. Peripheral CD8+ T cells transduced with 1G4α, 1G4β, or 1G4LYα were stimulated with IL-21-secreting wt-aAPC pulsed with heteroclitic A2/NY-ESO-1 peptide once a week. Between stimulations, IL-2 (10 IU/ml) and IL-15 (10 ng/ml) were added every 3 days. Data for A2/NY-ESO-1 multimer staining conducted after second stimulation are shown (left). Data are representative of two donors. 1G4α-transduced CD8+ T cells were costained with A2/NY-ESO-1 multimer, mAbs for TCR TRBV subtypes, and anti-CD8 mAb. The percentage of A2/NY-ESO-1 multimer+ CD8+ T cells expressing each subtype after second stimulation is shown (right). (B), Peripheral T cells transduced with 1G4α hemichain are highly avid for A2/NY-ESO-1 recognition. 1G4α-transduced or non-transduced CD8+ T cells were stimulated with mut-aAPC pulsed with heteroclitic NY-ESO-1 peptide and used as responder cells in IFN-γ ELISPOT analysis. T2 cells pulsed with 10 μg/ml A2/HIV control or A2/NY-ESO-1 peptide were used as stimulator cells (left). Various target cells, which did or did not express HLA-A2 and/or NY-ESO-1, were used as stimulator cells (right). Experiments were carried out in triplicate and error bars depict SD. *P < 0.05.

HHS Vulnerability Disclosure